Nicotinic acid and other therapies for raising high-density lipoprotein

Current Opinion in Cardiology

Volumn 21, Issue 4, 2006, Pages 336-344

  Carlson, Lars A ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b NONE   (Sweden)

Author keywords

Atherosclerotic cardiovascular disease; Combined treatment; High density lipoproteins; Nicotinic acid; Statins

Indexed keywords

HIGH DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; DISEASE COURSE; HUMAN; LIFESTYLE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

ANTILIPEMIC AGENTS; ATHEROSCLEROSIS; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIFE STYLE; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; NIACIN; RISK FACTORS; TREATMENT OUTCOME;

EID: 33748205451     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hco.0000231404.76930.e9     Document Type: Review

References (76)

1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Studies (4S). Lancet 1994; 344:1383-1389.
2. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 260:7-22.
3. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301-1307.
4. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998; 279:1615-1622.
5. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled study. Lancet 2004; 364:685-696.
6. Robinson JG, Smith B, Maheshwari N, Schrott H. Pleiotropic effects of statin: benefit beyond cholesterol reduction? A meta-regression analysis. J Am Coll Cardiol 2005; 46:1855-1862.
7. LaRosa JC. Editorial comment. At the heart of the statin benefit. J Am Coll Cardiol 2005; 46:1863.
8. Chapman MJ, Assman G, Fruchart JC, et al. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid - a position paper developed by the European consensus panel on HDL-C. Curr Med Res Opin 2004; 20:1253-1286.
9. Chapman MJ. Beyond the statins: new therapeutic perspectives in cardiovascular disease prevention. Cardiovasc Drugs Therapy 2005; 18:135-139.
10. Kastelein JJP. Future strategies in the management of dyslipidemia. Future Cardiol 2005; 1:1-4.
11. Myers CD, Kashyap ML. Pharmacologic augmentation of high-density lipoproteins: mechanisms of currently available and emerging therapies. Curr Opin Cardiol 2005; 20:307-312.
12. Barr DP, Russ EM, Eder HA. Protein-lipid relationship in human plasma. II In atherosclerosis and related conditions. Am J Med 1951; 11:480-493.
13. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart disease. Lancet 1975; i:16-19.
14. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977; 62:707-714.
15. Genest IJ, McNamara. Salem DN, et al. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol 1991; 67:1185-1189.
16. Weverling AWE. High-density vs low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age. Arch Int Med 2004; 163:1549-1554.
17. Olsson AG, Schwartz GG, Szarek M, et al. High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial. Eur Heart J 2005; 26:853-855. In acute coronary syndromes baseline HDL-C but not LDL-C predicted the outcome within 4 months. For each 1 mg/dl increase in HDL-C there was a 1.4% reduction of risk of ASCVD events.
18. Beaumont JL, Carlson LA, Cooper GR, et al. Classification of hypelipidemias and hyperlipoproteinemias. Bull WHO 1970; 43:891-915.
19. Lipid Research Clinics Program Epidemiology Committee. Plasma lipid distributions in selected North American populations: the Lipid Research Clinics Program Prevalence Study. Circulation 1979; 60:427-439.
20. Assman G, Nofer JR. The protective role of HDL. In: Carlson LA, editor. Lectures in clinical atherosclerosis and dyslipidaemia. London: Science Press; 2004. pp. 1-58.
21. Vaughan AM, Oram JF. ABCG1 redistributes cell cholesterol to domains removable by high density lipoprotein but not by lipid-depleted apolipoproteins. J Biol Chem 2005; 34:30150-30157. Describes the different effects on transport of intracellular cholesterol to cell-surface domains by cassette-binding transporters ABCA1 and ABCG1.
22. Johansson J, Carlson LA, Landou C, Hamsten A. High-density lipoproteins and coronary atherosclerosis. Arterioscler Thromb 1991; 11:174-182.
23. Asztalos BF, Collins D, Cupples A, et al. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham offspring study. Arterioscler Thromb Vasc Biol 2004; 24:2181-2187.
24. King AC, Haskell WL, Young DR, et al. Long-term effects of varying intensities and formats of physical activitiy on participation rates, fitness and lipoproteins in men and women aged 50 to 65 years. Circulation 1995; 91:2596-2604.
25. Couillard C, Després JP, Lamarche B, et al. Effects of endurance training on plasma HDL cholesterol depend on level of triglyceride: evidence from men of the Health, Risk factors. Exercise training and genetics (HERITAGE) family study. Arterioscler Thromb Vasc Biol 2001; 21:1226-1232.
26. Maeda K, Noguchi Y, Fukul T. The effect of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis. Prev Med 2003; 37:283-290.
27. Garrison RJ, Kannel WB, Feinleib M, et al. Cigarrette smoking and HDL cholesterol: the Framingham offspring sudy. Atherosclerosis 1978; 30:17-25.
28. Meksawan K, Pendergast DR, Leddy H, et al. Effect of low and high fat diets on nutrient intakes and selected cardiovascular risk factors in sedentary men and women. J Am Coll Nutr 2004; 23:131-140.
29. Sjöström L, Lindroos AK, Peltonen M, et al. Life style, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351:2683-2693.
30. James WPT, Astrup A, Finer N, et al. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Lancet 2000; 356:2119-2125.
31. Altschul R, Hoffer A, Stephen JD. Influence of nicotinic acid on serum cholesterol in man. Arch Biochem 1955; 54:558-559.
32. Altschul R. The effect of nicotinic acid on blood levels of cholesterol and on experimental atherosclerosis [in German]. Ztschr f Kreislaufforsch 1956; 45:453-460.
33. Parsons WB, Flinn JH. Reduction of serum cholesterol levels and beta-lipoprotein cholesterol levels by nicotinic acid. Arch Int Med 1959; 103:783-790.
34. Carlson LA, Hamsten A, Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Int Med 1989; 226:271-276.
35. Carlson LA. The broad spectrum hypolipidaemic drug nicotinic acid. J Drug Dev 1990; 3 (suppl 1):223-226.
36. Carlson LA. Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad spectrum lipid drug. Int J Clin Pract 2004; 58:706-713.
37. McCormac PL, Keating GM. Prolonged-release nicotinic acid. A review of its use in the treatment of dyslipidaemia. Drugs 2005; 65:2719-2740.
38. Benyo Z, Gille A, Kero J, et al. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest 2005; 115:3634-3640.
39. Knopp RH, Alagona P, Davidson M, et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998; 47:1097-1104.
40. Morgan JM, Capuzzi DM, Guyton JR, et al. Treatment effect of Niaspan, a controlled release niacin, in patients with hypercholesterolemia: a placebo controlled study. J Cardiovasc Pharmacol Ther 1996; 1:195-202.
41. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975; 231:360-381.
42. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients. Long-term benefits with niacin. J Am Coll Cardiol 1986; 81:1245-1255.
43. Jacobson TA, Chin MM, Fromell GJ, et al. Fluvastatin with and without niacin for hypercholesterolemia. Am J Cardiol 1994; 74:149-154.
44. O'Keefe JH Jr. Effects of pravastatin with niacin or magnesium on lipid levels and prostprandial lipemia. Am J Cardiol 1995; 76:480-484.
45. Gardner SF. Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin. Pharmacotherapy 1996; 16:419-423.
46. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345:1583-1592.
47. Capuzzi DM, Morgan JM, Weiss RJ, et al. Beneficial effects of rosuvastatin alone and in combination with extended release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. Am J Cardiol 2003; 91:1304-1310.
48. Insull W Jr, McGovern ME, Schrott H, et al. Efficacy of extended-release niacin with lovastatin for hypercholesterolemia assessing all reasonable doses with innovative surface analysis. Arch Int Med 2004; 164:1121-1127.
49. Hunninghake DB, McGovern ME, Koren M, et al. A dose ranging study of a new, once-daily drug product containing extended-release niacin and lovastatin. Clin Cardiol 2003; 26:112-118.
50. Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002; 89:672-678.
51. Taylor AJ, Sullenberger LE, Lee HJ, et al. Arterial biology for the investigation of the teatment effects of reducing cholesterol (ARBITER) 2. A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004; 110:3512-3517.
52. Taylor AJ, Sullenberger LE, Lee HY. ARBITER 3: Atherosclerosis regression during open-label continuation of extended-release niacin following ARBITER 2. Circulation 2005; 111:e446. The continuation of ARBITER 2 showing that prolonged-release nicotinic acid induces regression of carotid atherosclerosis.
53. Carlson LA, Orö L. The effect of nicotinic acid on the plasma free fatty acids. Acta Med Scand 1962; 172:641-645.
54. Carlson LA, Orö L, Östman J. Effect of a single dose of nicotinic acid on plasma lipids in patients with hyperlipoproteinaemia. Acta Med Scand 1968; 183:457-465.
55. Karpe F, Frayn KN. The nicotinic acid receptor - a new mechanism for an old drug. Lancet 2004; 363:1892-1894.
56. Lorenzen A, Stannek C, Lang H, et al. Characterization of a G protein-coupled receptor for nicotinic acid. Mol Pharmacol 2001; 59:349-357.
57. Tunaru S, Kero J, Schaub A, et al. PUMA-G and HM74 are receptors for nicotinic acid and mediate its antilipolytic effect. Nat Med 2003; 9:352-355.
58. Jin FY, Kamanna VS, Kashyap ML. Niacin decreases removal of high density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for Reverse Cholesterol Transport Arterioscler Thromb Vasc Biol 1997; 17:2020-2028.
59. Ganji SH, Tanintharan S, Zhu D, et al. Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res 2004; 45:1835-1845.
60. Elam MB, Hunninhake DB, Davis KE, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. The ADMIT study: a randomised study. JAMA 2000; 284:1263-1270.
61. Grundy SM, Vega GL, McGovern ME, et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Arch Int Med 2002; 162:1568-1576.
62. Schaefer EJ, Asztalos BF. The effects of statins on high-density lipoproteins. Curr Atheroscler Rep 2006; 8:41-49. A good review on the subject.
63. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary artery disease: the Diabetes Intervention Study, a randomised study. Lancet 2001; 357:905-910.
64. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366:1849-1861. A large, controlled, randomized trial assessing the effect of normalizing diabetic dyslipidaemia with fenofibrate on cardiovascular endpoints. Total cardiovascular events were reduced, mainly due to a beneficial effect of non-fatal myocardial infarcts. The evaluation of the study results was hampered by an unfortunate higher intake of statins in the placebo group.
65. Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Int Med 2004; 164:2097-2104.
66. Saad MF, Greco S, Osei K, et al. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic subjects. Diabetes Care 2004; 27:1324-1329.
67. Black DM. Gut-acting drugs for lowering cholesterol. Curr Atherosclerosis Rep 2002; 4:71-75.
68. de Groth GJ, Kuivenhoven JA, Stalenhoel AFH, et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor JTT-705 in humans. Circulation 2002; 105:2159-2165.
69. Brousseau ME, Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesterol ester transfer protein on HDL cholesterol. N Engl J Med 2004; 350:1505-1515.
70. Chiesa G, Sirtori C. Apolipoprotein A-I Milano: current perspectives. Curr Opin Lipidol 2005; 14:159-163.
71. Carlson LA. Effect of a single infusion of recombinant human proapolipoprotein A-I liposomes (synthetic HDL) on plasma lipoproteins in patients with low high-density lipoprotein cholesterol. Nutr Metab Cardiovasc Dis 1995; 5:85-91.
72. Eriksson M, Carlson LA, Miettinen T, Angelin B. Stimulation of faecal sterol excretion after infusion of recombinant apo A-I. Potential reverse cholesterol transport in humans. Circulation 1999; 100:594-598.
73. Nissen SE, Tsunoda T, Tuscu EM, et al. Effect of recombinant apo A-I Milano on coronary atherosclerosis in patients with acute coronary syndrome: a randomized controlled trial. JAMA 2003; 290:2292-2300.
74. Navab M, Anantharamaiah GM, Reddy ST. Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol 2005; 25:1325-1331. An exciting new approach to exploring and using the protective properties of HDL.
75. VanGaal LF, Rissanen AM, Ziegler O, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365:1389-1397.
76. Després J-P, Golay A, Sjöström L, et al. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005; 353:2121-2134.